Inventor · disambiguated record
Jurg Tschopp
Also filed as: TSCHOPP JUERG · TSCHOPP JURG
12 granted patents·28 pending applications·320 citations·filing 1999–2019
92Inventor score
Top patents by PatentIndex Score
40 records- 0197US7083785B2Methods of treatment by administering an anti-BCMA antibodyBIOGEN IDEC INC·Filed 2002·Granted Aug 1, 2006·151 cites·18 claims
- 0294US7838639B2Antibodies to train R: a cysteine-rich member of the TNF-receptor family, and methods of treating tumors expressing said receptorBIOGEN IDEC INC·Filed 2008·Granted Nov 23, 2010·22 cites·11 claims
- 0393US9650430B2Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)BIOGEN MA INC·Filed 2014·Granted May 16, 2017·8 cites·10 claims
- 0493US6869605B2BAFF, inhibitors thereof and their use in the modulation of B-cell responseBIOGEN IDEC INC·Filed 2001·Granted Mar 22, 2005·75 cites·14 claims
- 0585US7385032B2Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteinsAPOTECH RES & DEV LTD·Filed 2002·Granted Jun 10, 2008·35 cites·12 claims
- 0684US10494416B2Methods of modulating immune responses using BCMA polypeptideBIOGEN MA INC·Filed 2017·Granted Dec 3, 2019·1 cites·7 claims
- 0780US7736657B2Fusion constructs containing active sections on TNF ligandsAPOXIS S A·Filed 2002·Granted Jun 15, 2010·15 cites·8 claims
- 0880US7223852B2Nucleic acids encoding TRAIN-R: a cysteine rich member of the TNF-receptor familyAPOXIS S A·Filed 2002·Granted May 29, 2007·8 cites·12 claims
- 0979US8828669B2Methods of screening for a compound that inhibits the interaction between BAFF and BCMABROWNING JEFFREY·Filed 2012·Granted Sep 9, 2014·1 cites·2 claims
- 1076US2020095305A1Methods of modulating immune responses using bcma polypeptideBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 1168US8895003B2Pharmaceutical composition comprising EDA-1 Fusion ProteinTOPOTARGET SWITZERLAND SA·Filed 2013·Granted Nov 25, 2014·2 cites·15 claims
- 1268US8501177B2Treatment of ectodermal dysplasia with EDA1 fusion proteinsGAIDE OLIVIER·Filed 2010·Granted Aug 6, 2013·2 cites·21 claims
- 1364US2010233179A1BAFF, inhibitors thereof and their use in the modulation of B-cell responseBROWNING JEFFREY·Filed 2009·Application pending·0 cites
- 1463US7402658B2TRAIN-R: a cysteine-rich member of the TNF-receptor familyBIOGEN IDEC INC·Filed 2006·Granted Jul 22, 2008·0 cites·10 claims
- 1559US2009053252A1Bimer or an oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteinsAPOTECH RES & DEV LTD·Filed 2008·Application pending·0 cites
- 1658US2005100548A1BAFF, inhibitors thereof and their use in the modulation of B-cell responseBIOGEN IDEC INC·Filed 2004·Application pending·0 cites
- 1756US2006079457A1BAFF, inhibitors thereof and their use in the modulation of B-cell responseBIOGEN IDEC INC·Filed 2005·Application pending·0 cites
- 1856US2011158993A1Train-R: A Cysteine Rich Member of the TNF-Receptor FamilyBIOGEN IDEC INC·Filed 2010·Application pending·0 cites
- 1955US2005169924A1BAFF, inhibitors thereof and their use in the modulation of B-cell responseBIOGEN IDEC INC·Filed 2005·Application pending·0 cites
- 2055US2013202552A1Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteinsLTD APOTECH RES AND DEV·Filed 2013·Application pending·0 cites
- 2154US2015004129A1Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteinsTOPOTARGET SWITZERLAND SA·Filed 2014·Application pending·0 cites
- 2254US2006084148A1April-a novel protein with growth effectsBIOGEN INC·Filed 2005·Application pending·0 cites
- 2353US2005112596A1APRIL-A novel protein with growth effectFiled 2004·Application pending·0 cites
- 2453US2015098944A1Fusion constructs containing active sections of tnf ligandsTOPOTARGET SWITZERLAND SA·Filed 2014·Application pending·0 cites
- 2553US2004235117A1Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteinsFiled 2004·Application pending·0 cites
- 2651US2012009211A1Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteinsTSCHOPP JUERG·Filed 2011·Application pending·0 cites
- 2749US2003138884A1APRIL- a novel protein with growth effectsBIOGEN INC·Filed 2002·Application pending·0 cites
- 2848US2009022704A1Method for the treatment of gout or pseudogoutAPOXIS SA·Filed 2007·Application pending·0 cites
- 2948US2007161559A1Method for the treatment of gout or pseudogoutAPOXIS SA·Filed 2006·Application pending·0 cites
- 3047US2005255547A1Hexamers of receptors, members of the tnf receptor family, their use in therapy and pharmaceutical compositions comprising the sameTSCHOPP JURG·Filed 2002·Application pending·0 cites
- 3145US2013302344A1Methods and medicaments for the treatment of gout or pseudogoutTOPOTARGET SWITZERLAND SA·Filed 2013·Application pending·0 cites
- 3241US2011262449A1Method for the treatment of gout or pseudogoutTOPOTARGET SWITZERLAND SA·Filed 2011·Application pending·0 cites
- 3341US2004115667A1Dna-sequences, which code for an apoptosis signal transduction proteinFiled 2001·Application pending·0 cites
- 3439US2004197876A1Recombinant fusion proteins and the trimers thereofFiled 2002·Application pending·0 cites
- 3539US2004209813A1Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseasesBUDD RALPH C·Filed 2004·Application pending·0 cites
- 3639US2005084876A1Flip genes and flip proteinsAPOXIS SA FORMERLY APOTECH RES·Filed 2004·Application pending·0 cites
- 3736US2004053292A1Proteins and dna sequences underlying these proteins used for treating inflammationsFiled 2001·Application pending·0 cites
- 3835US2004096450A1Methods and compositions for treating diseases associated with increased Fas-ligand titersFiled 2003·Application pending·0 cites
- 3934US2002086832A1Caspase inhibitors for inhibiting blood cell proliferation and for treating autoimmune diseasesAPOTECH RES & DEV LTD·Filed 2001·Application pending·0 cites
- 4021US2002095030A1Flip genes and flip proteinsFiled 1999·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jurg Tschopp files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →